The World Needs an AIDS Vaccine
Our vision:
a world without AIDS

Our mission:
ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world
We are at a critical juncture in AIDS vaccine research. An unprecedented flow of scientific breakthroughs and growing knowledge about HIV and the immune system are renewing energy and confidence. Researchers around the world are excitedly engaged in several new approaches. Yet while the epidemic continues to take an enormous toll on the lives of millions of people, particularly in the developing world, a misplaced perception that HIV/AIDS has become an easily managed disease makes it harder than ever to compete for increasingly constrained resources. Now is the time to raise our voices even more loudly to ensure the sustained support that will be needed to rid the world of AIDS once and for all.

In 2013, the AIDS vaccine field continued to advance multiple vaccine candidates, while making important discoveries that will guide the design of new approaches for the future. IAVI and our partners focused on advancing a few select, innovative approaches aimed at generating broad and long-lasting immunity against HIV. We learned a great deal more about targets on the surface of HIV for broadly neutralizing antibodies and advanced toward clinical development a first vaccine candidate to generate such antibodies. We commenced the first trial of an innovative approach in which a vector carries genetic instructions for an individual to produce their own broadly neutralizing antibodies. We completed enrollment of the first clinical trial of a novel replicating viral vector and moved others forward in preclinical studies. IAVI also expanded the Vaccine Product Development Center, supported by the Bill & Melinda Gates Foundation, providing services to help several of their grantees advance the development of promising vaccine candidates.

IAVI continued to work with many partners in sub-Saharan Africa, the epicenter of HIV/AIDS, to learn more about the disease, conduct epidemiology studies and clinical trials, and support researchers, clinicians and advocates so that they can lead the fight to halt this epidemic that devastates their families and communities. In 2013, we trained scientists, clinicians and community outreach workers in five African countries; informed important policies at regional, national and international levels; and facilitated collaborations within Africa and beyond, such as between South Africa and India.

On behalf of our colleagues and partners working tirelessly toward an AIDS vaccine, I extend heartfelt thanks to the many donors whose steadfast support continues to inspire and empower us, and to the many supporters and volunteers whose dedication keeps us focused and moving forward.

Together, we will achieve a world without AIDS.
Adding an AIDS vaccine to existing treatment and prevention would dramatically reduce the global spread of HIV. The following graphic shows how an AIDS vaccine could influence projected annual infections by 2050 at each of three levels of overall treatment and prevention coverage based on UNAIDS targets (one reflecting current trends and two additional scenarios reflecting enhancements).*

**Stop HIV infection once and for all**

**IAVI’s work is so important for us all. We must maintain the momentum in scientific research and development. A vaccine for HIV would offer hope to millions of people around the world. It will be needed, together with other new HIV prevention technologies, to end the AIDS epidemic and ensure that no one is left behind.”**

MICHEL SIDIBÉ
Executive Director, UNAIDS

---

**This graphic represents the potential impact of an AIDS vaccine as part of the UNAIDS Enhanced Investment Framework, IFE Modeling Project – UNAIDS, Futures Institute, IAVI, AVAC. This study is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of the International AIDS Vaccine Initiative and do not necessarily reflect the views of USAID or the United States Government.**

*An illustrative vaccine with an assumed efficacy of 60%, not representative of any specific candidate in development. Coverage reaches 70% in generalized HIV/AIDS epidemics, 80% in concentrated epidemics.*
How We Work

 › Understand the Epidemic
 › Catalyze Innovation
 › Develop a Vaccine for Those Most in Need

As a not-for-profit, globally operating Product Development Partnership (PDP), IAVI works with academic, government, industrial and NGO partners to connect innovative science with clinical development capabilities, translating laboratory breakthroughs into promising vaccine candidates.

IAVI conducts and supports AIDS vaccine discovery research focused on two key scientific challenges: understanding HIV’s extensive global variability, and the need to provide broad and lasting immunity that addresses this variability. Our discovery work is closely integrated with our translational research capabilities, enabling IAVI to accelerate promising approaches into clinical testing. To date, we have helped to develop 26 AIDS vaccine candidates, advancing the most promising to clinical trials, including 15 trials in sub-Saharan Africa and India.

Our science, pursued with many partners, focuses on:

• Discovery and development of vaccine candidates capable of eliciting broadly neutralizing antibodies (bNAbs) to prevent HIV infection;

• Discovery and development of replicating viral vector-based vaccine candidates capable of preventing and controlling HIV infection; and

• Providing product development services to the broader AIDS vaccine field to help advance the most promising candidates into clinical development.

IAVI catalyzes innovation through partnerships and investments such as our Neutralizing Antibody Consortium and its central hub at The Scripps Research Institute in La Jolla, California, and specialized laboratories in New York, New Delhi (a joint venture with the Government of India) and London (a partnership with Imperial College). We have extensive research and clinical partnerships with institutions in developing countries where the burden of HIV/AIDS is highest, such as Nairobi University and the Uganda Virus Research Institute—helping to inform scientific, epidemiological and policy research and analysis; ensuring that our efforts are focused where a vaccine is most needed; and strengthening sub-Saharan Africa’s knowledge, skills and technology.

The IAVI community encompasses scientists, advocates, clinicians and community workers—on our staff (such as those featured at right), as well as many partners across the world.

Our alliances and programs in Africa increase the potential for greater African participation in more upstream AIDS vaccine research.

“I know firsthand the misery that HIV/AIDS causes among the men and especially the women of Africa. I am proud to put my scientific knowledge and skills toward finding a vaccine that can help erase this scourge forever.”
Gaudensia Mutua, Scientist with the Kenya AIDS Vaccine Initiative, a collaboration of Nairobi University, the U.K. Medical Research Council and IAVI

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“IAVI is a responsible and transparent steward of the funds entrusted to us.”
Patrick Mouton, New York

“IAVI is a responsible and transparent steward of the funds entrusted to us.”
Patrick Mouton, New York

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe

“The IAVI community encompasses scientists, advocates, clinicians and community workers—on our staff (such as those featured at right), as well as many partners across the world.”

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“With our civil society partners, we communicate the need that translates into political and financial support.”
Arwa Meijer, Amsterdam

“Scientists and advocates must create a unified voice that makes the strongest case for an AIDS vaccine.”
Prince Bahati, Nairobi

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“With our civil society partners, we communicate the need that translates into political and financial support.”
Arwa Meijer, Amsterdam

“Scientists and advocates must create a unified voice that makes the strongest case for an AIDS vaccine.”
Prince Bahati, Nairobi

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“With our civil society partners, we communicate the need that translates into political and financial support.”
Arwa Meijer, Amsterdam

“Scientists and advocates must create a unified voice that makes the strongest case for an AIDS vaccine.”
Prince Bahati, Nairobi

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“With our civil society partners, we communicate the need that translates into political and financial support.”
Arwa Meijer, Amsterdam

“Scientists and advocates must create a unified voice that makes the strongest case for an AIDS vaccine.”
Prince Bahati, Nairobi

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“With our civil society partners, we communicate the need that translates into political and financial support.”
Arwa Meijer, Amsterdam

“Scientists and advocates must create a unified voice that makes the strongest case for an AIDS vaccine.”
Prince Bahati, Nairobi

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe

“Our alliances and programs in Africa increase the potential for greater African participation in more upstream AIDS vaccine research.”

“IAVI is a responsible and transparent steward of the funds entrusted to us.”
Patrick Mouton, New York

“IAVI is a responsible and transparent steward of the funds entrusted to us.”
Patrick Mouton, New York

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“With our civil society partners, we communicate the need that translates into political and financial support.”
Arwa Meijer, Amsterdam

“Scientists and advocates must create a unified voice that makes the strongest case for an AIDS vaccine.”
Prince Bahati, Nairobi

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe

“We all aspire to successfully overpower the challenging foe that is HIV and return to a world free of AIDS.”
Bimal Chakrabarti, New Delhi

“With our civil society partners, we communicate the need that translates into political and financial support.”
Arwa Meijer, Amsterdam

“Scientists and advocates must create a unified voice that makes the strongest case for an AIDS vaccine.”
Prince Bahati, Nairobi

“I am privileged to work alongside communities of people who most need a vaccine.”
Leslie Nielsen, Entebbe
Advancing the Science

Since 2009, several pivotal broadly neutralizing antibodies (bNAbs) found through the landmark Protocol G study by members of our Neutralizing Antibody Discovery/Immunobiology and Immunogen Design groups has helped partners from the Beth Israel Deaconess Medical Center and Oxford University identify and develop these bNAbs as candidate leads.

As part of IAVI’s work to achieve cellular immune responses and broadly neutralizing antibodies (bNAbs), we continue to identify and test highly conserved HIV epitopes. A first candidate moved into the clinic in 2013. As part of our joint HIV Vaccine Translational Research Laboratory in New Delhi, leading to discovery of a novel candidate based on the HIV strain that circulates in India.

At the University of Oxford to identify and test highly conserved HIV epitopes. A first candidate moved into the clinic in 2013. In 2013, teams led by members of our Neutralizing Antibody Discovery/Immunobiology and Immunogen Design groups has helped partners from the Beth Israel Deaconess Medical Center and Oxford University identify and develop these bNAbs as candidate leads.

In the Laboratory

IAVI and partners discovered a simian relative of HIV. In 2013, teams led by members of our Neutralizing Antibody Discovery/Immunobiology and Immunogen Design groups has helped partners from the Beth Israel Deaconess Medical Center and Oxford University identify and develop these bNAbs as candidate leads.

In the Community

In 2013, IAVI and our partners worked with Community Advisory Board members from Zambia, Uganda, Rwanda, and the United Kingdom, finding a voice between the laboratory and the real world—what matters to people in their daily lives.

In the international arena in 2013, IAVI worked with civil society partners and other product implementers to plan improved community outreach, including the creation of a national advisory board in Tanzania. IAVI helped partners from the BethIsrael Deaconess Medical Center and Oxford University identify and develop these bNAbs as candidate leads.

In the Community

IAVI and our partners worked with Community Advisory Board members from Zambia, Uganda, Rwanda, and the United Kingdom, finding a voice between the laboratory and the real world—what matters to people in their daily lives.

In the international arena in 2013, IAVI worked with civil society partners and other product implementers to plan improved community outreach, including the creation of a national advisory board in Tanzania. IAVI helped partners from the BethIsrael Deaconess Medical Center and Oxford University identify and develop these bNAbs as candidate leads.

In the Community

IAVI and our partners worked with Community Advisory Board members from Zambia, Uganda, Rwanda, and the United Kingdom, finding a voice between the laboratory and the real world—what matters to people in their daily lives.

In the international arena in 2013, IAVI worked with civil society partners and other product implementers to plan improved community outreach, including the creation of a national advisory board in Tanzania. IAVI helped partners from the BethIsrael Deaconess Medical Center and Oxford University identify and develop these bNAbs as candidate leads.
Advancing the Science

Since 2009, several potent broadly neutralizing antibodies (bNAbs) found through the landmark Protocol G study by members of our Neutralizing Antibody Discovery team and our other researchers have helped inform and support regional and national decision-making in the countries hit hardest by HIV/AIDS. Based on this research, IAVI helped form partnerships with the Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute to develop additional candidates to protect against the HIV strain that circulates in South Africa and Uganda.

As part of IAVI’s efforts to achieve cellular immune responses that are the foundation of durable control of HIV, we are developing a virus-like particle (VLP) vaccine for HIV-1 and a vaccine based on the Sendai virus and delivered intranasally. In collaboration with the Japanese biotech DNAVEC, we advanced a vector vaccine based on the Sendai virus and delivered intranasally to challenge the dominant hypothesis that HIV vaccines must be based on viral vectors for strong and lasting prevention of HIV. Working with the Children’s Hospital of Philadelphia and the University of Oxford, we started the first trial to evaluate whether vaccines based on adenovirus-26 antigens can elicit durable protective immunity against infection by the simian relative of HIV. In 2013, teams led by researchers at the University of Oxford detailed the molecular structure of HIV’s surface protein where these antibodies bind—an achievement that we and partners quickly began translating into a new vaccine candidate for clinical testing. In parallel, IAVI and partners discovered that AAV vectors can be used to deliver HIV-1 neutralizing antibodies to the lungs, raising the possibility of a new class of vaccines to target sites using Protocol G antibodies.

We are also providing public health leadership and technical support toward the development of candidate vaccines for future clinical trials, to training local doctors and researchers, and to sharing evidence with regional, national and global health, research and development agendas at the local, national and regional levels for the next 15 years.

Etiologies of Viral Illnesses

In the Laboratory

In the Community

CLINICAL DEVELOPMENT PARTNERSHIPS

The International AIDS Vaccine Initiative (IAVI) is an independent, nonprofit corporation based in New York, which promotes research and development and community engagement to help inform and support regional and national decision-making in the countries hit hardest by HIV/AIDS. IAVI works with many partners to engender the political, regulatory, scientific and ethical environment necessary to drive forward the research and development and clinical testing of HIV/AIDS vaccines. We are also providing technical support toward the development of candidate vaccine candidates for future clinical trials.

In 2013, IAVI contributed to Kenya’s landmark HIV prevention implementation of the country’s first ever HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas. In Uganda, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas. In 2013, IAVI and our partners worked with Community Advisory Board members in a rural Ugandan, Research funded by the National Institutes of Health and the Bill & Melinda Gates Foundation to help them inform and lower the barriers of fear and stigma that hinder health services for people who are heard and well served in all protocols and trials, including future AIDS vaccine trials. In Kenya, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas. The International AIDS Vaccine Initiative (IAVI) is an independent, nonprofit corporation based in New York, which promotes research and development and community engagement to help inform and support regional and national decision-making in the countries hit hardest by HIV/AIDS. IAVI works with many partners to engender the political, regulatory, scientific and ethical environment necessary to drive forward the research and development and clinical testing of HIV/AIDS vaccines. We are also providing technical support toward the development of candidate vaccine candidates for future clinical trials.

In the International Arena

In the United States, IAVI supports the National Institutes of Health’s (NIH) HIV Vaccine Research Program (HVRP), which helps develop durable protective immunity against HIV. In 2013, IAVI contributed to Kenya’s landmark HIVVAX implementation of the country’s first ever HIVVAX trials, including the development of national and international stakeholder support to keep AIDS vaccine research high on their agendas. In Uganda, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas. In 2013, IAVI and our partners worked with Community Advisory Board members in a rural Ugandan, Research funded by the National Institutes of Health and the Bill & Melinda Gates Foundation to help them inform and lower the barriers of fear and stigma that hinder health services for people who are heard and well served in all protocols and trials, including future AIDS vaccine trials. In Kenya, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas.

In the International Arena

In the United States, IAVI supports the National Institutes of Health’s (NIH) HIV Vaccine Research Program (HVRP), which helps develop durable protective immunity against HIV. In 2013, IAVI contributed to Kenya’s landmark HIVVAX implementation of the country’s first ever HIVVAX trials, including the development of national and international stakeholder support to keep AIDS vaccine research high on their agendas. In Uganda, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas. In 2013, IAVI and our partners worked with Community Advisory Board members in a rural Ugandan, Research funded by the National Institutes of Health and the Bill & Melinda Gates Foundation to help them inform and lower the barriers of fear and stigma that hinder health services for people who are heard and well served in all protocols and trials, including future AIDS vaccine trials. In Kenya, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas.

In the International Arena

In the United States, IAVI supports the National Institutes of Health’s (NIH) HIV Vaccine Research Program (HVRP), which helps develop durable protective immunity against HIV. In 2013, IAVI contributed to Kenya’s landmark HIVVAX implementation of the country’s first ever HIVVAX trials, including the development of national and international stakeholder support to keep AIDS vaccine research high on their agendas. In Uganda, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas. In 2013, IAVI and our partners worked with Community Advisory Board members in a rural Ugandan, Research funded by the National Institutes of Health and the Bill & Melinda Gates Foundation to help them inform and lower the barriers of fear and stigma that hinder health services for people who are heard and well served in all protocols and trials, including future AIDS vaccine trials. In Kenya, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas.

In the International Arena

In the United States, IAVI supports the National Institutes of Health’s (NIH) HIV Vaccine Research Program (HVRP), which helps develop durable protective immunity against HIV. In 2013, IAVI contributed to Kenya’s landmark HIVVAX implementation of the country’s first ever HIVVAX trials, including the development of national and international stakeholder support to keep AIDS vaccine research high on their agendas. In Uganda, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas. In 2013, IAVI and our partners worked with Community Advisory Board members in a rural Ugandan, Research funded by the National Institutes of Health and the Bill & Melinda Gates Foundation to help them inform and lower the barriers of fear and stigma that hinder health services for people who are heard and well served in all protocols and trials, including future AIDS vaccine trials. In Kenya, we helped develop a similar advisory mechanism for the national HIVVAX trials, to building local and international stakeholder support to keep AIDS vaccine research high on their agendas.
Financial Snapshot

**ASSETS**
- Cash & Investments: 64.7M
- Loans/Interest Receivables: 16.0M
- Grants Receivable: 14.7M
- Fixed Assets: 15.6M
- Other: 1.4M
- **TOTAL ASSETS** $112.4M

**LIABILITIES** $47.9M

**NET ASSETS** $64.5M

**TOTAL LIABILITIES & NET ASSETS** $112.4M

**Revenue**
- Government Grants and Contributions: 43.9M
- Private Sector Organizations/Individuals: 14.5M
- Investment Income & Other: 1.9M
- **Total** $60.3M

**Program vs. Non-Program Expenses**
- Research & Development: 46.9M
- Advocacy, Policy & Communications: 6.8M
- Administration: 6.9M
- Fundraising: 2.4M
- **Total** $63.0M

**R&D Program by Focus Area**
- Neutralizing Antibodies: 29%
- Clinical Development: 33%
- Replicating Vectors: 74%
- Vaccine Product Development Center: 73%

Data as of 31 December 2013. Complete audited financial statements are available at www.iavi.org.
Achieving a world without AIDS will require greater access to prevention and treatment for all, the end of stigma and discrimination, and scientific progress to develop new therapeutic and preventative tools. Today HIV is pushing research for a cure and a vaccine onto entirely new—and increasingly common—ground, where researchers can learn a great deal from each other toward our common goal.”

FRANÇOISE BARRÉ-SINOUISSI
Nobel laureate and Immediate Past President, International AIDS Society
The spread of HIV cannot be fully controlled without a vaccine. I commend IAVI for their continued focus on this difficult goal, which I have no doubt science will ultimately solve. We look forward to the day when we work with countries to roll out the vaccine.”

SETH BERKLEY
CEO, Gavi, the Vaccine Alliance, and IAVI founder

“It will take many organizations working together with sustained funding to develop an AIDS vaccine, which will be needed to defeat this global killer once and for all. IAVI’s combination of innovative vaccine research and a broad range of partnerships is a promising model to get there.”

MARK DYBUL
Executive Director, The Global Fund to Fight AIDS, Tuberculosis and Malaria